Table 2.

Case-control analysis of rs198977 in the KLK2 gene in three studies of prostate cancer

Nam et al. (11)CGEMS (27)CAPS1CAPS2CAPS1 + CAPS2
Cases, n (%)
    C/C335 (52)618 (53)788 (56)670 (55)1,458 (56)
    C/T260 (40)472 (40)515 (37)460 (38)975 (37)
    T/T50 (8)80 (7)94 (7)89 (7)183 (7)
Controls, n (%)
    C/C356 (59)630 (57)443 (61)483 (57)926 (59)
    C/T216 (36)404 (37)233 (32)287 (34)520 (33)
    T/T34 (6)63 (6)48 (7)72 (9)120 (8)
P (3 × 2 table)0.0380.0790.0880.190.029
Heterozygote OR (95% CI)1.3 (1.0-1.6)1.2 (1.0-1.4)1.2 (1.0-1.5)1.2 (0.96-1.4)1.2 (1.0-1.4)
Homozygote OR (95% CI)1.6 (1.0-2.5)1.3 (0.91-1.8)1.1 (0.76-1.6)0.89 (0.64-1.2)1.0 (0.76-1.2)
Hardy-Weinberg P (controls)0.90.90.0250.0020.0001

NOTE: Data for the combined cohort of CAPS1 and CAPS2 are included for informational purposes in the last column; these two cohorts were considered separately in the meta-analysis.